Enveric Biosciences, Inc. (NASDAQ: ENVB) told investors it has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (NPP) to Vancouver, BC-based MindBio Therapeutics (CNSX: MBIO), a clinical-stage biopharma company, which is pioneering novel treatments for psychiatric conditions using microdoses of psychedelic medicines.
